Mogamulizumab (Poteligeo)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 22:01, 6 June 2014 by Jwarner (talk | contribs) (Created page with "=Mechanism of action= Defucosylated anti-cc chemokine receptor 4 (CCR4) antibody =Preliminary results= # Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto ...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Mechanism of action

Defucosylated anti-cc chemokine receptor 4 (CCR4) antibody

Preliminary results

  1. Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, Suzumiya J, Inagaki H, Tamura K, Akinaga S, Tomonaga M, Ueda R. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014 Apr 10;32(11):1157-63. Epub 2014 Mar 10. link to original article PubMed